- US-listed companies
- Dermata Therapeutics, Inc.
Dermata Therapeutics, Inc.DRMA
Market cap
$7.18M
P/E ratio
Dec 31, 2021 | Dec 31, 2022 | |
Research and development | 3 | 6 |
General and administrative | 4 | 4 |
Total operating expenses | 8 | 10 |
Loss from operations | -7,856,864 | -9,674,486 |
Interest (income) expense, net | - | 63,573 |
Net loss | -7,902,477 | -9,610,913 |
Net loss attributable to common stockholders | -10,464,714 | -9,610,913 |
Net loss per share of common stock, basic and diluted | -2.43 | -0.87 |